Evidence map›Paper›PMID 35516440›Full record

ArticleFrontiers in microbiology2022

Oral Shedding of an Oncogenic Virus Alters the Oral Microbiome in HIV+ Patients.

Lu Dai, Yong-Chen Lu, Jungang Chen, Karlie Plaisance-Bonstaff, Shengyu Mu, J Craig Forrest, Denise Whitby, Steven R Post, Zhiqiang Qin

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Lu DaiDepartment of Pathology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, United States.
Yong-Chen LuDepartment of Pathology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, United States.
Jungang ChenDepartment of Pathology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, United States.
Karlie Plaisance-BonstaffDepartment of Medicine, Louisiana State University Health Sciences Center, Louisiana Cancer Research Center, New Orleans, LA, United States.
Shengyu MuDepartment of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, AR, United States.
J Craig ForrestDepartment of Microbiology and Immunology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, United States.
Denise WhitbyViral Oncology Section, AIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD, United States.
Steven R PostDepartment of Pathology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, United States.
Zhiqiang QinDepartment of Pathology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, United States.
University of Arkansas for Medical Sciences · USLeidos (United States) · USLouisiana Cancer Research Center · USWinthrop Rockefeller Foundation · US

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Expanding Translational Research in ArkansasUL1TR003107 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI JAMES, LAURA P · 2019 to 2023
$21.6M
T cell homing to the kidney contributes to salt retention and blood pressure regulationR01HL146713 · NHLBI · UNIV OF ARKANSAS FOR MED SCIS · PI Shengyu Mu · 2019 to 2026
$4.2M
Institutional Career DevelopmentKL2TR003108 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI ARTHUR, JOHN M., BORSHEIM, ELISABET · 2019 to 2023
$2.3M
Periodontal bacteria enhance oral KSHV pathogenesis and Kaposi’s Sarcoma development in HIV+ patientsR01CA228166 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI FORREST, JAMES CRAIG, POST, STEVEN · 2018 to 2023
$1.9M
NCATS NIH HHS KL2 TR003108NCATS NIH HHS UL1 TR003107NCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003INCI NIH HHS R01 CA228166NHLBI NIH HHS R01 HL146713NIH HHS 75N91019D00024
6 · The paper itself

Abstract

Kaposi's Sarcoma (KS) caused by Kaposi's sarcoma-associated herpesvirus (KSHV) continues to be the most common AIDS-associated tumor. Involvement of the oral cavity represents one of the most common clinical manifestations of this tumor. Numerous types of cancer are associated with the alterations of in components of the microbiome. However, little is known about how KSHV coinfection affects the oral microbiome in HIV+ patients, especially in a "pre-cancer" niche. Using 16S rRNA pyrosequencing, we found that oral shedding of KSHV correlated with altered oral microbiome signatures in HIV+ patients, including a reduction in the microbiota diversity, changing the relative composition of specific phyla and species, and regulating microbial functions. Furthermore, we found that

Indexed as

HIVKSHVmicrobiomeoncogenic virusoral microbiota

Identifiers

PMID35516440
PMCPMC9063630
OpenAlexW4224294223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.